Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

Bibliographic Details
Main Authors:	Kelsey E. Hirotsu, MD, Vivian Hua, BA, Anhthy T. Tran, MSN, Laura Morris, BSN, Sunil A. Reddy, MD, Bernice Y. Kwong, MD, Lisa C. Zaba, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	JAAD Case Reports
Subjects:	cutaneous oncology herpes immunosuppressed Merkel cell carcinoma oncodermatology talimogene laherparepvec
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512621003362

Similar Items

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
by: Dimitrios C. Ziogas, et al.
Published: (2022-06-01)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
by: Howard L. Kaufman, et al.
Published: (2017-09-01)

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
by: Paul V. Ohnesorge, et al.
Published: (2022-06-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
by: Ibrahim Ragab Eissa, et al.
Published: (2017-07-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Erythematous desquamating rash after initiation of chemotherapy
by: Jack Newcomer, BA, et al.
Published: (2023-04-01)

High-dose vitamin D for the management acute radiation dermatitis
by: Cuong V. Nguyen, MD, et al.
Published: (2023-09-01)

Merkel Cells
Published: (2008-09-01)

Pseudocellulitis in oncology patients: A single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy
by: Jolanta J. Pach, BS, et al.
Published: (2023-09-01)

DETECTing Merkel Cell Polyomavirus in Merkel Tumors
by: Reety Arora, et al.
Published: (2020-02-01)

Merkel cell carcinoma: multiple primary skin lesions in the lower limb
by: Bruna Margatho Elias, et al.
Published: (2022-12-01)

Merkel Cell Carcinoma
by: Elena Dellambra, et al.
Published: (2021-06-01)

Epidemiology of Merkel Cell Polyomavirus Infection and Merkel Cell Carcinoma
by: Steffi Silling, et al.
Published: (2022-12-01)

Merkel cell polyomavirus and associated Merkel cell carcinoma
by: June F. Yang, et al.
Published: (2022-06-01)

Total remission of Merkel cell carcinoma after coronavirus infection: a case report
by: Lucas Henrique Rigon Vidoto, et al.
Published: (2023-05-01)

Merkel cell carcinoma of the abdominal wall
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
by: Clara Esnault, et al.
Published: (2022-02-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
by: Kate E. Beekman, BS, et al.
Published: (2023-03-01)

From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis
by: Nathan A. Krump, et al.
Published: (2021-09-01)

Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1
by: Celestino Velásquez, et al.
Published: (2018-04-01)

Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service
by: Jolanta J. Pach, BS, et al.
Published: (2024-06-01)